Glenn Davis
Family Medicine · Manchester, TNNPI 1497757298
Payments from drug & device makers
Across 359 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Lilly USA, LLC$434
- Astellas Pharma US Inc$420
- AstraZeneca$408
- Novartis$346
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,890100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,151 |
| AbbVie(2 entities) | 57 | $1,108 |
| Lilly USA, LLC | 30 | $434 |
| Astellas Pharma US Inc | 25 | $420 |
| AstraZeneca | 18 | $408 |
| Novartis | 19 | $346 |
| Pfizer | 16 | $254 |
| Johnson & Johnson | 20 | $216 |
| Otsuka America Pharmaceutical, Inc. | 9 | $149 |
| GSK | 10 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $136 |
| Bayer | 6 | $132 |
| Jazz Pharmaceuticals Inc. | 5 | $105 |
| Amgen | 5 | $96 |
| Boehringer Ingelheim | 5 | $90 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Merck | 5 | $68 |
| Amarin Pharma, Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Dexcom, Inc. | 3 | $51 |
| Abbott | 3 | $42 |
| Corcept Therapeutics | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $31 |
| Almatica Pharma LLC | 1 | $29 |
| Eisai Inc. | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Gilead | 1 | $24 |
| Alkermes, Inc. | 1 | $21 |
| Inogen, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Shire North American Group Inc | 1 | $11 |
| Endogastric Solutions, Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$5,890 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 67 | $91,969 |
| EliquisApixaban | 141 | $87,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $68,217 |
| FarxigaDapagliflozin Propanediol | 57 | $55,972 |
| XareltoRivaroxaban | 46 | $55,573 |
| OzempicSemaglutide | 38 | $38,612 |
| JardianceEmpagliflozin | 26 | $21,308 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $14,112 |
| BelsomraSuvorexant | 16 | $10,879 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,511 |
| JanuviaSitagliptin Phosphate | 12 | $7,921 |
| EntrestoSacubitril/Valsartan | 11 | $7,197 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,800 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $6,279 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 181 | $6,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,151 | $130,580105 claims |
| PfizerEliquis | $254 | $87,820141 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $140 | $77,72896 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $408 | $76,88394 claims |
| Johnson & JohnsonXarelto | $216 | $55,57346 claims |
| MerckBelsomra, Januvia, Janumet | $68 | $24,79739 claims |
| Boehringer IngelheimJardiance | $90 | $21,30826 claims |
| NovartisEntresto | $346 | $7,19711 claims |
| Almatica Pharma LLCSertraline Hcl | $29 | $1,246149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Manchester
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.